Eisai's Alzheimer's drug reduces cognitive decline by 27% in trial patients

In this video

Share

Eisai's Alzheimer's drug reduces cognitive decline by 27% in trial patients

Eisai Co. Chairman and CEO for the U.S. Ivan Cheung joins 'Closing Bell' to discuss promising results from the company's latest drug trial for Alzheimer's, and the anticipated cost of the drug if it becomes publicly available.
03:57
Wed, Sep 28 20224:00 PM EDT